Related Experiment Video

Updated: Sep 23, 2026

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

Vitamin B1 blocks damage caused by hyperglycemia

Mark E Obrenovich1, Vincent M Monnier

  • 1Department of Pathology at Case Western Reserve University, Cleveland, OH 44106, USA. vmm3@po.cwru.edu

Science of Aging Knowledge Environment : SAGE KE
|July 8, 2003
PubMed

Insights

Benfotiamine, a vitamin B1 derivative, may prevent diabetes complications by activating transketolase. This vitamin derivative helps divert harmful metabolites, protecting against diabetic retinopathy and metabolic damage.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Cell Biology

Background:

  • Diabetes accelerates aging and causes severe complications like blindness and cardiovascular disease.
  • High glucose levels in diabetes lead to mitochondrial dysfunction and damage to key enzymes like GAPDH.
  • This damage activates detrimental metabolic pathways: advanced glycation end-products, protein kinase C, and hexosamine pathways.

Purpose of the Study:

  • To investigate the potential of benfotiamine, a vitamin B1 derivative, in preventing diabetes-related metabolic damage.
  • To explore the mechanism by which benfotiamine might counteract hyperglycemia-induced cellular damage.

Main Methods:

  • Diabetic rats were treated with high doses of benfotiamine.
  • The study assessed the impact of benfotiamine on key metabolic pathways and diabetic complications, specifically retinopathy.

Main Results:

  • Benfotiamine treatment prevented diabetic retinopathy in rats.
  • It also prevented the activation of the three major metabolic damage pathways implicated in diabetes.
  • The protective effect was attributed to stimulated transketolase activity, which diverts metabolites to the pentose pathway.

Conclusions:

  • Benfotiamine shows promise in preventing diabetic complications and associated metabolic damage.
  • The findings suggest a therapeutic role for benfotiamine in managing diabetes, though further clinical data is needed.

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...